Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Boaz Hirshberg_2023
VIEWPOINTS

Boaz Hirshberg, SVP, Clinical Development at Regeneron Shares Insights from the US FDA Approval of Evkeeza (evinacumab-dgnb)

Shots: Boaz spoke about the US FDA approval of Evkeeza (evinacumab-dgnb) to treat children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH) Boaz also talked about the study design of the pivotal pediatric trial evaluating Evkeeza(evinacumab-dgnb) . He then extended his talk on HoFH and how Regeneron is creating awareness about the disease The…
July 31, 2023

Read more

Exclusive Webinar Global Market Research Strategies for the Healthcare Industry
EVENTS

Exclusive Webinar: Global Market Research Strategies for the Healthcare Industry

Do you want to gain a competitive edge and make informed decisions for your healthcare business? Market research is a crucial process that plays a fundamental role in the success of businesses, organizations, and entrepreneurs alike. It involves gathering and analyzing relevant information about the target market, customers, competitors, and industry trends to make informed…
July 27, 2023

Read more

VIEWPOINTS_Kathleen Somera-Molina1_2023
VIEWPOINTS

Kathleen Somera-Molina, Head of SMA Global Medical Affairs at Biogen Shares Insights on New Data Published about SPINRAZA

Shots: Kathleen spoke about the results of a new study published in Advances in Therapy evaluating real-world adherence to SPINRAZA (nusinersen) with its unique dosing schedule among people with spinal muscular atrophy (SMA) She also talked about the overall adherence rates to nusinersen. She highlighted that adherence was higher during the maintenance phase than the loading phase…
July 24, 2023

Read more

VIEWPOINTS_Ivy Weng_2023
VIEWPOINTS

Ivy Weng, Group VP, of Life Sciences at Komodo Health Shares Insights on its Collaboration with Intercept Pharmaceuticals

Shots: Ivy shared details of its collaboration with Intercept Pharmaceuticals and how Intercept is using Komodo’s tech platform and healthcare map for a retrospective real-world study on the long-term outcomes for Ocaliva She also talked about how pharma companies can utilize Komodo’s technology platform and how it supports rare disease research The interview gives an…
July 20, 2023

Read more

VIEWPOINTS_Nabil Abadir_2023
VIEWPOINTS

Nabil Abadir, CMO and Head of Global Medical Affairs at Amarin Corp Shares Insights from New Data Evaluating Vascepa/Vazkepa at ACC.23/WCC

Shots: Nabil spoke about the data evaluating Vascepa/Vazkepa and eicosapentaenoic acid in reducing cardiovascular events presented at the ACC.23/WCC He also told our readers about the new analysis from the REDUCE-IT trial showing the effectiveness of VASCEPA/VAZKEPA in patients with recent acute coronary syndrome The interview shows how Amarin is developing innovative therapies, increasing the…
July 18, 2023

Read more

VIEWPOINTS_Olivier Harari_2023
VIEWPOINTS

Olivier Harari, VP, Early Clinical Development at Regeneron Shares his Views on Pozelimab’s BLA Acceptance for the US FDA Priority Review

Shots: Olivier highlighted the P-II/III data based on which Regeneron’s BLA for Pozelimab was accepted by the US FDA under priority review to treat adults and children with CHAPLE disease CHAPLE disease is driven by an overactivation of the complement system due to CD55 deficiency. Pozelimab blocks the activity of complement factor C5 and prevents…
July 17, 2023

Read more

Load more